Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

ClinicalTrials.gov ID: NCT03432533

Public ClinicalTrials.gov record NCT03432533. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab Via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab Via Prefilled Syringe

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)

Study identification

NCT ID
NCT03432533
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
283 participants

Conditions and interventions

Eligibility (public fields only)

Age range
55 Years to 90 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 5, 2018
Primary completion
Apr 10, 2019
Completion
Jan 7, 2020
Last update posted
Nov 22, 2020

2018 – 2020

United States locations

U.S. sites
35
U.S. states
19
U.S. cities
33
Facility City State ZIP Site status
Research Site Birmingham Alabama 35205
Research Site Birmingham Alabama 35294
Research Site Huntsville Alabama 35801
Research Site Tuscaloosa Alabama 35406
Research Site Chandler Arizona 85224
Research Site Mesa Arizona 85213
Research Site Cypress California 90630
Research Site Fullerton California 92835
Research Site Glendale California 91206
Research Site Laguna Hills California 92653
Research Site Santa Maria California 93454
Research Site Tustin California 92780
Research Site Denver Colorado 80230
Research Site Golden Colorado 80401
Research Site Delray Beach Florida 33446
Research Site South Miami Florida 33143
Research Site Atlanta Georgia 30319
Research Site Atlanta Georgia 30342
Research Site Bridgeton Missouri 63044
Research Site Springfield Missouri 65802
Research Site Las Vegas Nevada 89148
Research Site Great Neck New York 11021
Research Site Charlotte North Carolina 28204
Research Site Fargo North Dakota 58103
Research Site Cincinnati Ohio 45242
Research Site Duncansville Pennsylvania 16635
Research Site Wyomissing Pennsylvania 19610
Research Site Spartanburg South Carolina 29303
Research Site Summerville South Carolina 29486
Research Site San Antonio Texas 78209
Research Site Salt Lake City Utah 84107
Research Site Chesapeake Virginia 23320
Research Site Danville Virginia 24541
Research Site Renton Washington 98057
Research Site Franklin Wisconsin 53132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03432533, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03432533 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →